Search

Displaying results 3321 - 3330 of 7607 in total
  1. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  2. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine. It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. Doxecitine is currently approved ...

  3. Drug

    Deferoxamine

    go.drugbank.com/drugs/DB00746
    ApprovedInvestigational

    Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

  4. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.

  5. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  6. Drug

    Lazuvapagon

    go.drugbank.com/drugs/DB19046
    Investigational

    Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).

    Synonyms: (4s)-n-((2s)-1-hydroxypropan-2-yl)-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-2,3,4,5-tetrahydro-1h-1-benzazepine-4-carboxamide, 1h-1-benzazepine-4-carboxamide, 2,3,4,5-tetrahydro-n-((1s)-2-hydroxy-1-methylethyl)-4-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-, (4s)-
  7. Drug

    Nimacimab

    go.drugbank.com/drugs/DB15115
    Investigational

    Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).

  8. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group.

    Mixtures: N/A, LAVUZID® N
  9. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.